At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 3, 2026 at 16:19 ET
InMed Pharmaceuticals filed a prospectus supplement to its shelf registration statement to sell up to $1,213,648 worth of common shares through an at-the-market offering with H.C. Wainwright & Co. This is a routine capital raise under an existing agreement.
- InMed Pharmaceuticals filed a prospectus supplement on April 3, 2026, to sell up to $1,213,648 of common shares.
- The offering is conducted through an at-the-market (ATM) agreement with H.C. Wainwright & Co., originally dated April 7, 2022, and amended June 27, 2024.
- The shares are being offered under a shelf registration statement (Form S-3, File No. 333-294503) declared effective on March 30, 2026.
- The filing includes a legal opinion confirming the legality of the securities being registered.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access